DR. DAVID ROBERT WU, PHARMD
Pharmacy at Valley Blvd, Alhambra, CA

License number
California 75777
Category
Pharmacy
Type
Pharmacist
Address
Address 2
703 W Valley Blvd, Alhambra, CA 91803
1110 S 5Th Ave, Arcadia, CA 91006
Phone
(626) 289-1990

Personal information

See more information about DAVID ROBERT WU at radaris.com
Name
Address
Phone
David Wu, age 57
4473 Mazzoni Ter, Dublin, CA 94568
David Wu
459 36Th St, Oakland, CA 94609
(510) 655-1868
David Wu, age 66
45583 Bridgeport Dr, Fremont, CA 94539
David Wu, age 42
4516 Mirano Ct, Dublin, CA 94568
David Wu, age 78
4271 N 1St St SPC 164, San Jose, CA 95134

Professional information

David S Wu Photo 1

Dr. David S Wu, Arcadia CA - MD (Doctor of Medicine)

Specialties:
Anesthesiology
Address:
Pacific Valley Medical Group
300 W Huntington Dr, Arcadia 91007
(800) 275-8752 (Phone)
Northridge Office
8331 Reseda Blvd, Northridge 91324
(818) 993-3428 (Phone), (818) 993-3469 (Fax)
Certifications:
Anesthesiology, 1997
Awards:
Healthgrades Honor Roll
Languages:
English, Spanish
Hospitals:
Pacific Valley Medical Group
300 W Huntington Dr, Arcadia 91007
Northridge Office
8331 Reseda Blvd, Northridge 91324
Methodist Hospital of Southern California
300 West Huntington Dr, Arcadia 91007
Northridge Hospital Medical Center
18300 Roscoe Blvd, Northridge 91325
Education:
Medical School
University Of Pittsburgh School Of Medicine
Graduated: 1990
Loma Linda University Med Center
Graduated: 1991
Graduated: 1994


David Wu Photo 2

Generation Of Tumor-Free Embryonic Stem-Like Pluripotent Cells Using Inducible Recombinant Rna Agents

US Patent:
2009020, Aug 13, 2009
Filed:
Jan 8, 2009
Appl. No.:
12/318806
Inventors:
David TS Wu - Arcadia CA, US
International Classification:
C12N 15/86, C12N 15/74
US Classification:
435456, 435455, 4353201
Abstract:
The present invention generally relates to a method for developing, generating and selecting tumor-free embryonic stem (ES)-like pluripotent cells using electroporation delivery of an inducible tumor suppressor mir-302 agent into mammalian cells. More particularly, the present invention relates to a method and composition for generating a Tet-On/Off recombinant transgene capable of expressing a manually re-designed mir-302 microRNA (miRNA)/shRNA agent under the control of doxycyclin (Dox) in human somatic/cancer cells and thus inducing certain specific gene silencing effects on the differentiation-associated genes and oncogenes of the cells, resulting in reprogramming the cells into an ES-like pluripotent state.